Novo Nordisk A/S

Summary

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Idea

Novo Nordisk was founded in 1923 by two Danish brothers, August and Harald Krogh, with the idea of developing and manufacturing insulin for people with diabetes. The company has since grown to become the world's largest insulin producer and a leading developer of treatments for other serious chronic diseases, including obesity, hemophilia, and growth disorders.

Mission Statement

Novo Nordisk's mission is to "drive change to defeat serious chronic diseases." The company does this by pioneering scientific breakthroughs, expanding access to its medicines, and working to prevent and ultimately cure the diseases it treats.

Segments

Novo Nordisk operates in three segments:

• Diabetes Care: This segment develops and manufactures insulin and other products for the treatment of diabetes.
• Obesity & Metabolism: This segment develops and manufactures products for the treatment of obesity and other metabolic diseases.
• Biopharmaceuticals: This segment develops and manufactures products for the treatment of hemophilia, growth disorders, and other rare diseases.

Revenue Breakdown by Sector

In 2022, Novo Nordisk's revenue breakdown by sector was as follows:

• Diabetes Care: 64%
• Obesity & Metabolism: 20%
• Biopharmaceuticals: 16%

Projects

Novo Nordisk is currently working on a number of projects to develop new treatments for serious chronic diseases. These include:

• A new long-acting insulin that is designed to be more effective and easier to use.
• A new drug for the treatment of obesity that works by targeting the brain's appetite control center.
• A new gene therapy for the treatment of hemophilia.

Novo Nordisk's flagship weight-loss drug Ozempic gained approval in late 2017/early 2018 and has been responsible for a large chunk of its revenues since. In 2021 they released their a more recent weight-loss drug 'WeGovy' which has since been widely successful as well. Aside from weight-loss medications Novo Nordisk is one of the worlds biggest insulin manufacturers.

Leadership

Novo Nordisk is led by Lars Fruergaard Jørgensen, who has been the company's CEO since 2017. Jørgensen is a Danish businessman who has held a number of senior positions at Novo Nordisk, including CEO of the company's diabetes care segment.

Ownership Structure

Novo Nordisk is a publicly traded company on the Copenhagen Stock Exchange. The largest shareholder is Novo Holdings A/S, a Danish investment company that is owned by the families of the company's founders. Novo Holdings owns approximately 25% of Novo Nordisk's shares.

Corporate Strategy

Novo Nordisk's corporate strategy is to become the leading global healthcare company in the fight against serious chronic diseases. The company plans to achieve this by:

• Pioneering scientific breakthroughs in the treatment of diabetes and other chronic diseases.
• Expanding access to its medicines to patients around the world.
• Working to prevent and ultimately cure the diseases it treats.

Novo Nordisk is a leading global healthcare company with a strong commitment to fighting serious chronic diseases. The company is constantly innovating and developing new treatments to improve the lives of patients around the world.